SIGA vs REGN vs GILD vs VRTX vs MRNA

For growth investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger pick with 9.

6% revenue growth year-over-year, versus -39. 2% for Moderna, Inc. (MRNA). SIGA Technologies, Inc. (SIGA) offers the better valuation at 14. 3x trailing P/E (2. 8x forward), making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, SIGA Technologies, Inc.

(SIGA) is the cheapest at 14. 3x versus Vertex Pharmaceuticals Incorporated at 27. 7x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2. 43x versus Vertex Pharmaceuticals Incorporated's 2. 68x.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to -70. 2% for Moderna, Inc. (MRNA). Over 10 years, the gap is even starker: SIGA returned +764. 0% versus GILD's +87. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Gilead Sciences, Inc.

(GILD) is the lower-risk stock at 0. 66β versus Moderna, Inc. 's 1. 82β — meaning MRNA is approximately 176% more volatile than GILD relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 109% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vertex Pharmaceuticals Incorporated (VRTX) is pulling ahead at 9.

6% versus -39. 2% for Moderna, Inc. (MRNA). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to -60. 2% for SIGA Technologies, Inc.. Over a 3-year CAGR, VRTX leads at 10. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus -145. 2% for Moderna, Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus -158. 1% for MRNA. At the gross margin level — before operating expenses — GILD leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2. 43x versus Vertex Pharmaceuticals Incorporated's 2. 68x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, SIGA Technologies, Inc. (SIGA) trades at 2. 8x forward P/E versus 22. 2x for Vertex Pharmaceuticals Incorporated — 19. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRTX: 29. 9% to $552. 27.

In this comparison, SIGA (12.

7% yield), GILD (2. 4% yield), REGN (0. 5% yield) pay a dividend. VRTX, MRNA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 12. 7% yield, +764. 0% 10Y return). Moderna, Inc. (MRNA) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +764. 0%, MRNA: +161. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SIGA is a small-cap deep-value stock; REGN is a mid-cap deep-value stock; GILD is a mid-cap quality compounder stock; VRTX is a mid-cap quality compounder stock; MRNA is a mid-cap quality compounder stock. SIGA, GILD pay a dividend while REGN, VRTX, MRNA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.